Navigation Links
Vanda Pharmaceuticals to Participate in Stifel Nicolaus Global Healthcare Conference and Jefferies Fall 2011 Mid-Atlantic Corporate Access Day
Date:8/31/2011

ROCKVILLE, Md., Aug. 31, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced that Mihael H. Polymeropoulos, M.D., Vanda President and CEO will deliver a corporate presentation at the Stifel Nicolaus Global Healthcare Conference in Boston, MA on Thursday, September 8, 2011 at 4:25 pm Eastern Time.  

Dr. Polymeropoulos' presentation at the Stifel Nicolaus Global Healthcare Conference will be available live on Vanda's corporate website, where it also will be archived for 30 days.  To access the presentation, log on to http://www.vandapharma.com and click on the Presentations option in the Investor Relations section. Please connect to the website several minutes prior to the start of the live presentation.

On Friday, September 9, 2011, members of the Vanda executive management team will participate in the Jefferies Fall 2011 Mid-Atlantic Corporate Access Day held in Baltimore, MD.    

About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders. For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com.

Company Contact:
Cristina Murphy
Communications Manager
Vanda Pharmaceuticals Inc.
(240) 599-4500
cristina.murphy@vandapharma.com


'/>"/>
SOURCE Vanda Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Vanda Pharmaceuticals Reports Second Quarter 2011 Results
2. Vanda Pharmaceuticals to Announce Second Quarter 2011 Financial Results on August 4, 2011
3. Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Probiomed S.A. de C.V. for Commercialization of Fanapt™ in Mexico
4. Vanda Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference
5. Vanda Pharmaceuticals Announces Date of Annual Meeting of Stockholders
6. Vanda Pharmaceuticals to Announce First Quarter 2011 Financial Results on May 5, 2011
7. Vanda Pharmaceuticals Announces Commencement of Clinical Study of Long-Acting Injectable Formulation of Fanapt®
8. Vanda Pharmaceuticals to Evaluate Tasimelteon in Major Depression
9. Vanda Pharmaceuticals Receives Orphan Drug Designation in Europe for tasimelteon
10. Vanda Pharmaceuticals Files Shelf Registration Statement
11. Vanda Pharmaceuticals Appoints Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Calif. , Oct. 11, 2017  BioPharmX Corporation ... scientific team that developed an innovative way to use ... of the delivery of new drugs. ... Fall Clinical Dermatology Conference will show how researchers from ... Hospital, Harvard Medical School used a suite of imaging ...
(Date:10/10/2017)... Oct. 10, 2017   West Pharmaceutical Services, Inc. ... for injectable drug administration, today shared the results of ... for improving the intradermal administration of polio vaccines. The ... Summit in May 2017 by Dr. Ondrej Mach ... World Health Organization (WHO), and recently published in the ...
(Date:10/4/2017)... , Oct. 4, 2017 ... single-use, self-contained, illuminating medical devices, today announced regulatory ... Health Surveillance Agency (or Agência Nacional de Vigilância ... first single-use, cordless surgical retractor with integrated LED ... optimal access, illumination and exposure of a tissue ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s premier ... of the shoulder pad. The shoulder pad provides optimal support and full contact ... using cold therapy. By utilizing ice and water that is circulated from an insulated ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
(Date:10/12/2017)... Washington, D.C. (PRWEB) , ... October 12, 2017 , ... ... of their peers in Washington, D.C., for the 49th Congress of the International ... Ph.D ., Vice President of the Center for Cancer and Blood Disorders ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy Innovations (HLI), ... software tool, and the Cancer Patient Education Network (CPEN), an independent professional organization ... a new strategic alliance. , As CPEN’s strategic partner, HLI will help ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... at the University of California Berkeley, and other leading institutions in announcing the ... power of institutions to change the way animals are raised for food. , ...
Breaking Medicine News(10 mins):